TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8227760

Group type: EXPERIMENTAL
Intervention: Disulfiram (800 mg) during dexamethasone and postdexamethasone days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Disulfiram-potentiated DST (DSTd)
Number of subjects: 35
Study: 3533256

Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study: 31339403

Group type: EXPERIMENTAL
Intervention: Group‐task‐oriented training (group‐TOT) for 1 hour, twice a week for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Individualized traditional physical and occupational therapy (comparison group)
Number of subjects: 18
Study: 29105252

Group type: EXPERIMENTAL
Intervention: New information resource
Number of subjects: 80

Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 80
Study: 27544584

Group type: EXPERIMENTAL
Intervention: qHPV vaccine (0.5mL) administered intramuscularly at months 0, 2, and 6
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 372
Study: 24871666

Group type: EXPERIMENTAL
Intervention: Wheat bran-inclusive diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study: 22736125

Group type: EXPERIMENTAL
Intervention: 1 day of bowel preparation
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 days of bowel preparation
Number of subjects: 60
Study: 20441133

Group type: EXPERIMENTAL
Intervention: Self-reported evaluations of problem seriousness, help-seeking importance, and prognosis when imagining oneself with depressive symptoms.
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Self-reported evaluations of problem seriousness, help-seeking importance, and prognosis when imagining a peer-group friend with depressive symptoms.
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Contextual effect of symptom severity presentation.
Number of subjects: 263
Study: 18676533

Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 mL daily from week 18 of pregnancy until 3 months after delivery)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Corn oil (10 mL daily from week 18 of pregnancy until 3 months after delivery)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Maternal plasma phospholipid concentrations of alpha-linolenic acid and docosahexaenoic acid during pregnancy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Fatty acid status at birth or during the first 3 months of life
Number of subjects: 143
Study: 18334948

Group type: EXPERIMENTAL
Intervention: lotrafilcon B (O2 Optix) with AQuify and ReNu MoistureLoc
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: galyfilcon A (Acuvue Advance) with AQuify and ReNu MoistureLoc
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both lens materials
Number of subjects: 48
Study: 15161072

Group type: EXPERIMENTAL
Intervention: IPV(vero)
Number of subjects: 129

Group type: COMPARATOR
Intervention: IPV(mkc)
Number of subjects: 129
Study: 9271616

Group type: EXPERIMENTAL
Intervention: Group Well Child Care (GWCC)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Individual Well Child Care (IWCC)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both GWCC and IWCC
Number of subjects: 210
Study: 7896932

Group type: EXPERIMENTAL
Intervention: Survey of attitudes and beliefs regarding clinical judgment research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey of knowledge of clinical judgment literature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey on the importance of clinical judgment research
Number of subjects: 0
Study: 3657165

Group type: EXPERIMENTAL
Intervention: Abstinence for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continued drinking as usual
Number of subjects: 60
Study: 30900065

Group type: EXPERIMENTAL
Intervention: Survivors of non-pulmonary cancers developing SPLC
Number of subjects: 1450837

Group type: EXPERIMENTAL
Intervention: Survivors of cancer of the hypopharynx, oropharynx, tonsil, and larynx
Number of subjects: 1450837

Group type: EXPERIMENTAL
Intervention: Survivors of bladder and esophageal cancer
Number of subjects: 1450837

Group type: EXPERIMENTAL
Intervention: Increasing age and being divorced/widowed/separated
Number of subjects: 1450837

Group type: COMPARATOR
Intervention: Comparison with control arm of the NLST
Number of subjects: 1450837
Study: 30526779

Group type: EXPERIMENTAL
Intervention: Modified brain protection double-lumen drainage tube
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional silicone drainage tube
Number of subjects: 49
Study: 26957375

Group type: EXPERIMENTAL
Intervention: Usual care with >8 months in the PCMH
Number of subjects: 4664

Group type: EXPERIMENTAL
Intervention: Automated mailed and centrally delivered stepped interventions
Number of subjects: 4664

Group type: COMPARATOR
Intervention: Usual care with <4 months in the PCMH
Number of subjects: 4664
Study: 24874315

Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg per day for 24 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Other drugs (control group)
Number of subjects: 45
Study: 22365947

Group type: EXPERIMENTAL
Intervention: Azosemide (long-acting loop diuretic)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Furosemide (short-acting loop diuretic)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Echocardiography and chest X-ray
Number of subjects: 98
Study: 20801763

Group type: EXPERIMENTAL
Intervention: MR spectroscopy in PMA
Number of subjects: 60

Group type: COMPARATOR
Intervention: MR spectroscopy in PLS
Number of subjects: 60

Group type: COMPARATOR
Intervention: MR spectroscopy in ALS-L and ALS-B
Number of subjects: 60

Group type: COMPARATOR
Intervention: MR spectroscopy in all groups
Number of subjects: 60

Group type: COMPARATOR
Intervention: NAAx and mIns levels
Number of subjects: 60
Study: 18300446

Group type: EXPERIMENTAL
Intervention: 24-hour pH monitoring with antacid treatment (omeprazole)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group with antacid treatment (omeprazole) only
Number of subjects: 50
Study: 16273995

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study: 12174378

Group type: EXPERIMENTAL
Intervention: Salvianolic acid B (SA‐B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interferon‐gamma (IFN‐gamma)
Number of subjects: 60
Study: 10450010

Group type: EXPERIMENTAL
Intervention: Bardex IC catheter
Number of subjects: 198

Group type: COMPARATOR
Intervention: Silicon catheter
Number of subjects: 198

Group type: COMPARATOR
Intervention: Latex catheter
Number of subjects: 198
Study: 2533866

Group type: EXPERIMENTAL
Intervention: 10 micrograms of B‐Hepavac II vaccine
Number of subjects: 84

Group type: COMPARATOR
Intervention: 5 micrograms of B‐Hepavac II vaccine
Number of subjects: 84
Study: 779705

Group type: EXPERIMENTAL
Intervention: Methadyl acetate (80 mg three times a week)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: High-dose methadone (50 mg daily or 100 mg daily)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Low-dose methadone
Number of subjects: 430
Study: 31464393

Group type: EXPERIMENTAL
Intervention: Original Riceberry rice pudding
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fiber Riceberry rice pudding
Number of subjects: 12

Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 12
Study: 28472530

Group type: EXPERIMENTAL
Intervention: Nutrition intervention for 3 months with individualized nutrition care plan plus monthly post-discharge telehealth follow-up
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Nutrition intervention for 3 months
Number of subjects: 148
Study: 26517656

Group type: EXPERIMENTAL
Intervention: 17D-213/77
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: 17DD
Number of subjects: 1966

Group type: EXPERIMENTAL
Intervention: Concomitant vaccination against measles, mumps and rubella
Number of subjects: 1966
Study: 23147558

Group type: EXPERIMENTAL
Intervention: SRP+SDD (20 mg of doxycycline twice daily)
Number of subjects: 174

Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 174
Study: 21059422

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 20024763

Group type: EXPERIMENTAL
Intervention: Condom use at last sex in non-spousal partnerships
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: New HIV infection
Number of subjects: 762
Study: 17519642

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg for 1 month, 5 mg for 2 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy + Olanzapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15375277

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15471832

Group type: EXPERIMENTAL
Intervention: 18F‐FLT PET
Number of subjects: 17

Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 17
Study: 11423814

Group type: EXPERIMENTAL
Intervention: Intravenous pyridoxine (5 g over 5 minutes)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous placebo (50 mL of normal saline solution)
Number of subjects: 5
Study: 9208341

Group type: EXPERIMENTAL
Intervention: Cholestyramine with cerivastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholestyramine pretreatment 1 hour before cerivastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholestyramine pretreatment 5 hours before cerivastatin
Number of subjects: 0
Study: 8094168

Group type: EXPERIMENTAL
Intervention: 50 mg aspirin daily until delivery
Number of subjects: 1106

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1106
Study: 3620286

Group type: EXPERIMENTAL
Intervention: Enprofylline with amoxycillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enprofylline with erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline with erythromycin
Number of subjects: 0
Study: 31940793

Group type: EXPERIMENTAL
Intervention: Convolutional neural network for PPI site prediction; improved data set; specific details on dosage and duration not applicable.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convolutional neural network for PPI site prediction; high binding propensity samples.
Number of subjects: 0
Study: 28664457

Group type: COMPARATOR
Intervention: Highest tertile of MCV
Number of subjects: 403

Group type: COMPARATOR
Intervention: Highest tertile of MCH
Number of subjects: 403

Group type: COMPARATOR
Intervention: Highest tertile of MCHC
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Combined second and third tertiles of MCV
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Combined second and third tertiles of MCH
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Combined second and third tertiles of MCHC
Number of subjects: 403
Study: 26938140

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 g)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg) and Acetaminophen (1 g)
Number of subjects: 300
Study: 25605843

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (fluorouracil, leucovorin, and irinotecan)
Number of subjects: 666

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 666
Study: 23263176

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART) initiated at enrollment (n = 139)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART) initiated when CD4 count <15% or CDC category C event developed (n = 145)
Number of subjects: 284

Group type: COMPARATOR
Intervention: HIV-uninfected children (n = 319)
Number of subjects: 284
Study: 21395483

Group type: COMPARATOR
Intervention: Oxycodone 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone 20/10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 15
Study: 18339123

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day) and Vitamin E (600 mg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No melatonin treatment
Number of subjects: 115
Study: 16797388

Group type: EXPERIMENTAL
Intervention: GLA 2.2% cream
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo-based cream
Number of subjects: 17
Study: 12506030

Group type: EXPERIMENTAL
Intervention: Blood stem cell recipients
Number of subjects: 87

Group type: COMPARATOR
Intervention: Marrow recipients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pretransplantation antibody levels in the recipient
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Donor pretransplantation antibody levels
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Patient or donor age, total body irradiation, and graft‐versus‐host disease or its treatment
Number of subjects: 87
Study: 10730983

Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion (1:9 mg/d) on Days 14 to 26 after estrus
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxytocin injections (0.33 USP units/kg body weight, s.c.) twice daily on Days 3 to 6 of the estrous cycle
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 25
Study: 10160459

Group type: EXPERIMENTAL
Intervention: On-line medical command (OLMC) randomization
Number of subjects: 87
Study: 1466940

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg) syrup, 2.5 mL twice daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo syrup, 2.5 mL twice daily
Number of subjects: 113
Study: 6429229

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31907033

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) using the PICO™ system
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard postsurgical wound care
Number of subjects: 38
Study: 30446822

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Psychoeducational group (OCD-EP)
Number of subjects: 125
Study: 27308725

Group type: EXPERIMENTAL
Intervention: Emotional Stroop Task (EST) with blocked presentation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Emotional Stroop Task (EST) with randomized presentation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-traumatized controls
Number of subjects: 67
Study: 25941925

Group type: EXPERIMENTAL
Intervention: Carbohydrate-casein hydrolysate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate-whey hydrolysate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate-only
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo-water
Number of subjects: 8
Study: 24405719

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 0
Study: 22529693

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stent placement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-stent group
Number of subjects: 120
Study: 20000282

Group type: EXPERIMENTAL
Intervention: Animal-assisted activity (weekly for 2 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no animal-assisted activity)
Number of subjects: 30
Study: 17322140

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 8 oz
Number of subjects: 13

Group type: COMPARATOR
Intervention: Grapefruit juice (GFJ) 8 oz
Number of subjects: 13
Study: 15356495

Group type: EXPERIMENTAL
Intervention: Extended prophylaxis regimen including regular mechanical tooth cleaning by a hygienist, scaling, and chlorhexidine treatment.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Initial prophylaxis alone consisting of patient motivation, oral hygiene checkups, and fluoridation.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient selection based on caries risk indicators.
Number of subjects: 80
Study: 12073159

Group type: EXPERIMENTAL
Intervention: THC-only (low dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: THC-only (high dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Whole-plant marijuana (low dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Whole-plant marijuana (high dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10445600

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1,000 microg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2,000 microg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group A: Low dose inhaled corticosteroids (< or =400 microg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group B: Oral corticosteroids (> or =10 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group C: Healthy untreated volunteers
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 33
Study: 7769071

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection with live spermatozoa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracytoplasmic injection with dead spermatozoa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracytoplasmic injection without a spermatozoon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection of human sperm cytosolic fraction (CF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection of human sperm cytosolic fraction (CF) in mouse oocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic injection of CF after heat treatment
Number of subjects: 0
Study: 2179521

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment for 26 days
Number of subjects: 19
Study: 435348

Group type: EXPERIMENTAL
Intervention: Metallized plastic sheeting (m.p.s.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 6849726

Group type: EXPERIMENTAL
Intervention: Methotrimeprazine 7.5 mg i.m.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methotrimeprazine (small non-sedative doses)
Number of subjects: 10
Study: 30579966

Group type: EXPERIMENTAL
Intervention: Fludarabine + Busulfan (FB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fludarabine + Thiotepa (FT)
Number of subjects: 60
Study: 30407932

Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Discontinuation of rTMS treatment based on cBEI
Number of subjects: 665
Study: 26403637

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Both groups (EES and SES)
Number of subjects: 195
Study: 25046950

Group type: EXPERIMENTAL
Intervention: Shen‐reinforcing and menstrual cycle‐regulating therapy combined with Western medicine (IM group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Western medicine (WM group)
Number of subjects: 78
Study: 22296973

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 · 2 mg daily for 6–10 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard ovarian stimulation protocol (Control)
Number of subjects: 86
Study: 20435238

Group type: EXPERIMENTAL
Intervention: ACTH + MgSO(4)
Number of subjects: 38

Group type: COMPARATOR
Intervention: ACTH (control)
Number of subjects: 38
Study: 18544168

Group type: EXPERIMENTAL
Intervention: Simple educational intervention for GPs
Number of subjects: 376

Group type: COMPARATOR
Intervention: Complex educational intervention for GPs (including clinical outreach visit)
Number of subjects: 376
Study: 14715345

Group type: EXPERIMENTAL
Intervention: Full-dose reteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Half-dose reteplase with full-dose abciximab
Number of subjects: 0
Study: 11689803

Group type: EXPERIMENTAL
Intervention: Adult ischemic preconditioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adult control
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Aged ischemic preconditioning
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aged control
Number of subjects: 80
Study: 9297428

Group type: EXPERIMENTAL
Intervention: rH‐EPO (200 U/kg body weight subcutaneously once a day, three days a week for 4 weeks) with oral ferrous sulfate (4 mg/kg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: rH‐EPO
Number of subjects: 58
Study: 7952423

Group type: EXPERIMENTAL
Intervention: Early percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Early medical therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 108

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 108
Study: 3674795

Group type: EXPERIMENTAL
Intervention: Oral physostigmine (mode = 13 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral physostigmine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31942840

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg) in addition to standard treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy non-diabetic pediatric subjects (control group)
Number of subjects: 49
Study: 29927937

Group type: EXPERIMENTAL
Intervention: Binge eating symptoms (BE)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Sexual trauma
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 817
Study: 27788877

Group type: EXPERIMENTAL
Intervention: Home-based asthma intervention
Number of subjects: 150
Study: 25188544

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Process-oriented training for health professionals
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control Group A (CGA) - No intervention
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control Group B (CGB) - No intervention
Number of subjects: 540